BCL2 and glioblastoma: Co-administration of vorinostat and the MEK inhibitor trametinib has demonstrated the ability to suppress malignant features of GBM cells while downregulating BCL-2 family genes and replacing trametinib with the BCL-2 inhibitor navitoclax seems to further enhance apoptosis [273].